Old medicines are still evaluated for ongoing safety profiles, including interactions with new classes of drugs that may come on the market. Users of these medicines benefit from this.

As an example, here's a 2018 study on Tylenol using the HEK 293 line: https://pubmed.ncbi.nlm.nih.gov/29273526/